Daclizumab inhibits CD40L expression independently of cell division in naive CD4+ T cells
| CD45RA . | Cell divisions at 48 hrs . | Total . | ||
|---|---|---|---|---|
| % Divided . | 2 . | 1 . | 0 . | |
| Control | 14 (6) | 47 (7) | 39 (13) | 100% |
| Daclizumab | 0 | 35 (11) | 65 (11) | 100% |
| % CD40L+ | 2 | 1 | 0 | Total |
| Control | 13 (5) | 40 (8) | 17 (3) | 70% |
| Daclizumab | 0 | 7 (3) | 11 (3) | 18% |
| CD45RA . | Cell divisions at 48 hrs . | Total . | ||
|---|---|---|---|---|
| % Divided . | 2 . | 1 . | 0 . | |
| Control | 14 (6) | 47 (7) | 39 (13) | 100% |
| Daclizumab | 0 | 35 (11) | 65 (11) | 100% |
| % CD40L+ | 2 | 1 | 0 | Total |
| Control | 13 (5) | 40 (8) | 17 (3) | 70% |
| Daclizumab | 0 | 7 (3) | 11 (3) | 18% |
Results shown are mean (± SE) of 4 donors.